Publications | Biocartis

Articles

Explore a selection of recent articles our company and collaborators have generated. We will continue to be active contributors to the scientific community, further advancing the delivery of precision medicine and improved patient outcomes.

The opinions and conclusions expressed in the following publications are those of the individual authors and do not necessarily reflect the views and opinions of Biocartis and/or its employees.

Get notified about our latest publications!

A review on the Idylla platform: towards the assessment of actionable genomic alterations in one day

Uguen & Troncone - J Clin Pathol. - September 2018

Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti–Epidermal Growth Factor Receptor Therapy

Maurel et al. - JCO Precision Oncology - April 2019

Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study

De Craene et al. - Annals of Oncology - 2018

Rapid somatic mutation testing in colorectal cancer by use of a fully automated system and single-use cartridge: a comparison with next-generation sequencing

Al-Turkmani et al. - JALM - August 2018

Multicenter evaluation of the Idylla NRAS-BRAF Mutation Test in metastatic colorectal cancer

Prieto-Potin et al.- J Mol Diagn. - September 2018

Multi-center evaluation of the fully automated PCR-based Idylla KRAS Mutation Assay for rapid KRAS mutation status determination on FFPE tissue of human colorectal cancer

Solassol et al. - PLoS One - September 2016

The data and conclusions provided in these publications have not been validated in the development of the Idylla™ Tests/Assays or included in the product's current labelling by Biocartis NV. Biocartis NV products are designed to be used as described in the product-specific instructions.

Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries.

Idylla™ BRAF, KRAS, NRAS-BRAF & EGFR Mutation Tests, and Idylla™ GeneFusion Panel are CE-marked in Europe in compliance with the EU IVD directive 98/79/EC, but are for Research Use Only (RUO), not for use in diagnostic procedures, in the US. Idylla™ MSI Test is CE-marked in Europe in compliance with the EU IVD directive 98/79/EC and cleared in the US under K211181.

Idylla™ BRAF, KRAS, ctKRAS, NRAS-BRAF-EGFR S492R, ctNRAS-BRAF-EGFR S492R, EGFR, ctEGFR & PIK3CA-AKT1 Mutation Assays; Idylla™ MSI & GeneFusion Assays; and Idylla™ IDH1-2 Mutation Assay Kit are available for Research Use Only (RUO), not for use in diagnostic procedures. Idylla™ ThyroidPrint® Assay is for Research Use Only (RUO), not for use in diagnostic procedures, developed by GeneproDX, and distributed by Biocartis.